Plenary Lecture

Pharmacological Approaches for the Neuroregeneration Therapies

Dr. Kiminobu Sugaya
Professor of Medicine
University of Central Florida

Abstract: Despite decades of investigations in both laboratory and clinic, the pathophysiological mechanism of Alzheimer’s disease (AD) still remains unknown. Current problem of developing AD research is that many treatments have been found to be very effective in AD animal models but they failed show significant effects in clinical trials. Thus, establishment of an effective treatment in a model to represent pathophysiology of AD is needed.
Previously, we were able to show improved cognitive function of aged, memory-impaired animals through the implantation of human neural stem cells (NSCs), which produced much excitement throughout the research world and the overall medical community; given the implication that this could lead to a cure for all neurodegenerative diseases, including AD. However, when we transplant NSCs to a transgenic animal model produces Amyloid-β (Aβ) plaque formation in the brain by expressing familial AD mutant amyloid precursor protein (APP), mimicking the pathological condition of AD, we did not find any new neuronal development formed from the donor cells. This indicates that transplantation of NSCs by itself may not be a cure for AD.
Here we show that the combination drug therapy of Posiphen (reduce amyloid protein precursor (APP) level) and NBI-18 (increase endogenous neural stem cell) increased neurogenesis and significantly improved memory in the transgenic AD mouse model. This combination therapy could bring us an effective treatment for AD. I will further discuss the use of iPS cell to confirm this efficacy in vitro 3D human AD brain model.

Brief Biography of the Speaker: Dr. Kiminobu Sugaya is a professor of medicine in Burnett School of Biomedical Science, College of Medicine, University of Central Florida (UCF) since 2004. He is a Director of Multidisciplinary Neuroscience Alliance of UCF and a Chair of Central Florida Chapter of Society for Neuroscience. He is conducting stem cell researches to treat neurodegenerative diseases by the adult stem cells. He recently received National Honor Plaque of Panama for exceptional contribution to neuroscience based on his study on stem cell therapies for neurodegenerative diseases from the President of Panama. His publication regarding improvement of memory in the aged animal by stem cell transplantation was reported Washington Post, BBC, NBC, ABC and other media in all over the world.
Dr. Sugaya He is also a founder and chair of Progenicyte, which is a biotech company holding his his 64 patent licenses. Among those are a revolutionary process of creating iPS (induced pluripotent stem) cells from a patient's own cells and a novel pharmacological approach to increase endogenous stem cells. With Dr. Sugaya's proprietary technologies covering all aspects of stem cell manipulations, Progenicyte is launching services to include: modified stem cell banking, genetic testing, and a commercial product to increase cellular regeneration which fights against aging.

Bulletin Board


The Conference Guide is online.

The paper submission deadline has expired. Please choose a future conference to submit your paper.

Plenary Speakers

WSEAS Main Site

Publication Ethics and Malpractice Statement